Cagrilintide + Semaglutide
110,00$
Description
This advanced peptide blend combines Cagrilintide, a long-acting amylin analog, with Semaglutide, a GLP-1 receptor agonist, to synergistically support appetite regulation, caloric intake reduction, and weight loss research. The combined action of these two peptides has demonstrated superior results in preclinical and clinical studies compared to monotherapy, making this blend highly relevant in the investigation of obesity, metabolic syndrome, and energy balance.
Epigenetix Labs provides this dual compound in research-grade purity, formulated for laboratory research only. It is not approved for human or veterinary use.
10 Research-Based Reasons to Study Cagrilintide + Semaglutide
- Synergistically reduces appetite via GLP-1 and amylin pathways
- Promotes significant weight reduction in obesity models
- Delays gastric emptying and enhances satiety signaling
- Lowers caloric intake more effectively than either peptide alone
- Improves glycemic control and insulin sensitivity
- Reduces visceral fat without compromising lean mass
- Targets multiple hypothalamic feeding centers
- Enhances leptin signaling and reduces ghrelin levels
- Mimics physiological postprandial hormone responses
- Useful in studies of metabolic syndrome and body recomposition
Additional information
Additional information
| Weight | 0,006 kg |
|---|---|
| Dimensions | 1,5 × 1,5 × 3,5 cm |
| Research Applications | Obesity and metabolic syndrome models |
| Key Research Findings | A pivotal study published in The New England Journal of Medicine (2021) demonstrated that the combination of Cagrilintide and Semaglutide led to over 17% body weight reduction in obese subjects—significantly more than either peptide alone. |
| Scientific Background | Semaglutide is a synthetic analog of glucagon-like peptide-1 (GLP-1), which stimulates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying, leading to reduced appetite and body weight in metabolic models. Cagrilintide is a stable analog of human amylin, a hormone co-secreted with insulin that also contributes to satiety signaling and energy intake reduction. When administered together, Semaglutide and Cagrilintide target complementary pathways in the hypothalamus and gut-brain axis, leading to amplified effects on appetite suppression and body weight reduction in obesity research. |
| Purity & Manufacturing Standards | This peptide blend from Epigenetix Labs is: • Synthesized via solid-phase peptide synthesis (SPPS) |
| Legal Disclaimer | For laboratory research use only. Not for human or veterinary use. Not for therapeutic, diagnostic, or food applications. Not evaluated by the FDA or regulatory authorities. |
| Size | 5 mg + 5 mg |
Reviews
There are no reviews yet.